40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

This study aims to explore the efficacy and adverse events of reduced-dose radiotherapy (40.2Gy) versus conventional-dose radiotherapy (49.2Gy) to low-risk target volume for chemosensitive intermediate-stage nasopharyngeal carcinoma patients.

Trial Details

NCT ID
NCT07328854
Phase
PHASE3
Sponsor
Ming-Yuan Chen
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Cisplatin-based induction chemotherapy
  • Full course of PD-1 monoclonal antibody
  • Reduced-dose radiotherapy to CTV2
  • Conventional-dose radiotherapy to CTV2
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Shantou, Guangdong, China|23.35489,116.67876

Key Eligibility Criteria

  • Patients are informed of the basic content of this study and sign an informed consent form;
  • Age between 18 and 75 years;
  • Pathologically diagnosed as non-keratinising nasopharyngeal carcinoma (differentiated or undifferentiated, i.e., WHO type II or III);
  • Staged according to the 9th edition of the AJCC/UICC TNM classification as T1-3N2M0 or T3N0-1M0 (Stage II);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →